Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis
Authors:
- 6 October 2021
- journal article
- editorial
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (2) , 1015-1018
Abstract
No abstract availableAll Related Versions
This publication has 16 references indexed in Scilit:
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2017
- Anticipatory nausea: current landscape and future directionsAnnals of Palliative Medicine, 2017
- Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic reviewSupportive Care in Cancer, 2015
- Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokinesSupportive Care in Cancer, 2015
- Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung CancerCell Biochemistry and Biophysics, 2015
- Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled StudyJournal of Pain and Symptom Management, 2014
- Consistency and inconsistency in network meta‐analysis: model estimation using multivariate meta‐regressionResearch Synthesis Methods, 2012
- Chemotherapy-induced nausea and vomiting—incidence and impact on patient quality of life at community oncology settingsSupportive Care in Cancer, 2006
- A review of the effect of atypical antipsychotics on weightPsychoneuroendocrinology, 2003
- Effect of postchemotherapy nausea and vomiting on health-related quality of lifeSupportive Care in Cancer, 1997